Ftse Mib
34.390,55
-1,25%
DAX
18.644,70
-0,65%
S&P 500
5.308,13
0,09%
NASDAQ
16.794,87
0,65%
Bitcoin
71.101,39
-0,49%

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Endo International PLC (ENDP) Endo International PLC (ENDP) Notizie

ENDP

Endo (ENDP)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:ENDP
DataOraFonteTitoloSimboloCompagnia
21/09/202313:45PR Newswire (Canada)Endo Presents New Data at the American Orthopaedic Foot & Ankle Society Annual MeetingNASDAQ:ENDPEndo International PLC
08/08/202313:45PR Newswire (US)ENDO REPORTS SECOND-QUARTER 2023 FINANCIAL RESULTSNASDAQ:ENDPEndo International PLC
18/07/202322:30PR Newswire (US)Endo Launches Bivalirudin Injection in Ready-to-Use VialsNASDAQ:ENDPEndo International PLC
13/07/202322:30PR Newswire (US)Endo Presents New Data at the American Podiatric Medical Association Annual MeetingNASDAQ:ENDPEndo International PLC
29/06/202322:31Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:ENDPEndo International PLC
12/06/202313:30PR Newswire (US)Endo Launches PREVDUO™ (neostigmine methylsulfate and glycopyrrolate injection), the First and Only FDA-Approved Neostigmine-Glycopyrrolate Combination Pre-Filled SyringeNASDAQ:ENDPEndo International PLC
08/05/202313:30PR Newswire (US)ENDO REPORTS FIRST-QUARTER 2023 FINANCIAL RESULTSNASDAQ:ENDPEndo International PLC
17/04/202313:45PR Newswire (US)Endo Announces Launch of Argatroban Injection Through Premier's ProRx® Private-Label ProgramNASDAQ:ENDPEndo International PLC
03/04/202322:30PR Newswire (Canada)Endo Launches Authorized Generic Version of Noxafil® (posaconazole) Oral SuspensionNASDAQ:ENDPEndo International PLC
13/03/202321:17PR Newswire (US)Endo Provides Top-Line Results from Phase 2 Study of Collagenase Clostridium Histolyticum (CCH) in Participants With Plantar FibromatosisNASDAQ:ENDPEndo International PLC
10/03/202313:30PR Newswire (US)Endo Launches First Generic Version of Pylera® (bismuth subcitrate potassium, metronidazole, tetracycline hydrochloride) CapsulesNASDAQ:ENDPEndo International PLC
06/03/202322:14Edgar (US Regulatory)Annual Report (10-k)NASDAQ:ENDPEndo International PLC
27/02/202323:15Edgar (US Regulatory)Post-effective Amendment to an S-8 Filing (s-8 Pos)NASDAQ:ENDPEndo International PLC
27/02/202323:00Edgar (US Regulatory)Post-effective Amendment to an Automatic Shelf Registration of Form S-3asr or Form F-3asr (posasr)NASDAQ:ENDPEndo International PLC
13/02/202318:39Edgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NASDAQ:ENDPEndo International PLC
06/02/202313:30PR Newswire (US)Endo Launches "Man With a Plan" Campaign to Support Men With Symptoms of Peyronie's DiseaseNASDAQ:ENDPEndo International PLC
31/01/202323:06Edgar (US Regulatory)Termination of Registration of a Class of Security Under Section 12(g) (15-12g)NASDAQ:ENDPEndo International PLC
06/12/202222:45PR Newswire (US)Endo to Cease Production and Sale of Qwo® (collagenase clostridium histolyticum-aaes)NASDAQ:ENDPEndo International PLC
09/11/202217:37Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:ENDPEndo International PLC
27/10/202213:30PR Newswire (US)Endo and SMSNA Launch App to Provide Peyronie's Disease Self-Assessment ToolNASDAQ:ENDPEndo International PLC
07/10/202213:30PR Newswire (US)Endo Presents New Qwo® (collagenase clostridium histolyticum-aaes) Data at the American Society for Dermatologic Surgery's Annual MeetingNASDAQ:ENDPEndo International PLC
05/10/202213:30PR Newswire (US)Endo Launches Unscripted Video Series With Real Dupuytren's Contracture PatientsNASDAQ:ENDPEndo International PLC
08/09/202219:44Edgar (US Regulatory)Statement of Ownership (sc 13g)NASDAQ:ENDPEndo International PLC
17/08/202212:32Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:ENDPEndo International PLC
17/08/202204:00PR Newswire (US)Endo Enters Into Restructuring Support Agreement with Senior Secured Debtholders to Strengthen Financial Position and Advance Ongoing Business TransformationNASDAQ:ENDPEndo International PLC
10/08/202220:08Dow Jones NewsEndo Bondholder Group Continues to Call on Company Not to File for BankruptcyNASDAQ:ENDPEndo International PLC
09/08/202215:00PR Newswire (US)New Drug Filing for Cenobamate Accepted for Review in Canada and IsraelNASDAQ:ENDPEndo International PLC
09/08/202214:45PR Newswire (US)ENDO REPORTS SECOND-QUARTER 2022 FINANCIAL RESULTSNASDAQ:ENDPEndo International PLC
08/08/202222:30PR Newswire (Canada)Laboratoires Paladin inc. annonce que Santé Canada a accepté la demande d'autorisation de mise sur le marché des comprimés de cénobamate comme traitement d'appoint pour la prise en charge des crises partielles chez les adultes atteints d'épilepsieNASDAQ:ENDPEndo International PLC
08/08/202222:30PR Newswire (Canada)Paladin Labs Announces Health Canada's Filing Acceptance of Cenobamate Tablets as an Adjunctive Therapy for the Management of Partial-Onset Seizures in Adults with EpilepsyNASDAQ:ENDPEndo International PLC
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:ENDP

La tua Cronologia

USOTC
AICLY
Asahi Intecc (PK)
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' CLICCA QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network